SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing significant volatility and upward momentum driven by intense short-squeeze dynamics, with investors closely watching a recent SEC filing regarding executive change-of-control agreements as a potential precursor to a buyout. The community is heavily focused on the scarcity of available shares, high borrow rates, and the anticipation of topline results from the Phase 3 REGAL trial for their lead AML immunotherapy.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following news that the FDA has scheduled an advisory committee meeting for its DMD therapy, a development that triggered short-term volatility as traders de-risked ahead of the upcoming decision date. Despite the market's reaction, the community remains heavily focused on the company's strong five-year clinical data, viewing the meeting as a potential opportunity to secure a broader product label rather than a sign of rejection.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is seeing heavy community debate as investors weigh the stock's multi-year lows against potential catalysts like tariff refunds and an upcoming leadership transition. While some traders are betting on a turnaround ahead of earnings, others remain cautious of structural issues and negative analyst sentiment.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is currently seeing high volatility and intense community discussion as investors weigh promising Ibsrela growth and strong fundamentals against persistent legal and reimbursement headwinds from the CMS bundling dispute. While some shareholders remain bullish on the long-term potential for profitability and acquisition, others are expressing frustration over stagnant price action and the ongoing regulatory uncertainty.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently seeing intense community debate and volatility, driven by ongoing efforts to position its solid oxide fuel cell technology as a critical, on-site energy solution for power-hungry AI data centers. Investors remain sharply divided between those viewing recent pullbacks as a buying opportunity based on long-term AI infrastructure backlogs and those expressing skepticism over the stock's valuation, share dilution, and the competitive threat from other energy alternatives.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum and bullish sentiment following a strong earnings report, with the community celebrating the company's shift toward high-growth software and QNX-powered physical AI. Investors are actively discussing upcoming catalyst opportunities and potential institutional re-ratings, pushing back against skeptics while maintaining conviction in the long-term turnaround.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as investors react to a new $6 billion share repurchase program, signaling management's confidence despite ongoing cyclical pressures in automotive and industrial markets. The community remains focused on the stock's potential for a long-term rebound, closely monitoring its performance as it navigates support levels and potential technical breakouts.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing heightened volatility and investor speculation as the market anticipates the potential allocation of FDA priority vouchers following recent executive orders supporting psychedelic therapy. The community is closely monitoring trial milestones for lead assets like BPL-003 and actively debating the stock's valuation disconnect and potential for a strategic partnership or buyout.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors react to a significant strategic agreement with Fit Energy to provide up to 380 megawatts of clean, on-site power for AI data centers. The community remains sharply divided between bulls pointing to the growing proposal pipeline and data center demand, and skeptics who are raising concerns over warrant structures, potential shareholder dilution, and the opacity of the partner involved.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant volatility driven by the positive reception of its long-term oncology trial data and a fresh FDA endorsement for its mRNA-based influenza vaccine candidate. While shareholders and the community are actively debating the company's transition beyond COVID-19 and the potential for a short squeeze, some remain skeptical, citing persistent concerns over regulatory headwinds and the long-term commercialization strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today 

Equity

Investors showed interest in businesses tied to artificial intelligence infrastructure, advanced biotechnology, and quantum computing.



$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) PR Newswire NEW YORK, June 23, 2026 NEW YORK, June 23, 2026 /PRNewswire...

BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History

Boundless Bio is set to merge with Serapha Bio, with the transaction set to close in the fourth quarter of 2026.

BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.Halper Sadeh encourages...

Market Movers Catching Transformational Catalysts

Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points. $NTHI, $BOLD, $BLZE, $CRWV, $PLTR, $ZETA, $ATLN, $HSCS

Big Money Backs Base Editing, as BOLD Deal Creates Well-Funded AATD Contender

The biotechnology sector continues to reward companies developing potentially transformative genetic medicines, particularly those addressing serious diseases with limited treatment options. The latest example emerged as Boundless Bio (NASDAQ:BOLD) announced a merger agreement with privately held Serapha Bio, a clinical-stage gene editing company developing an investigational treatment for Alpha-1 Antitrypsin Deficiency (AATD), alongside a substantial $230 million private financing commitment from a syndicate of prominent healthcare investors.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million.
Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to $2.28. Theread more...

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034)  DelveInsight

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...

Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why

Boundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in La Jolla, CA.

Boundless Bio Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.60	--	--	N/A
Q1 '26	-$0.58	-$0.60	-4.05%	MISSED
Q4 '25	-$0.52	-$0.58	-11.54%	MISSED
Q3 '25	-$0.58	-$0.62	-6.44%	MISSED
Q2 '25	-$0.65	-$0.70	-7.69%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

BOLDBoundless Bio Inc.

Latest Earnings Results: Q1 '26

Historical Earnings

Latest BOLD News